Q2 FY2026 · ended Jun 30, 2026 · Revenue $8.17M, +21.4% YoY · Filed Aug 10, 2026
Bionano Genomics, Inc. (BNGO) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $8.2 million and a net loss of $7.4 million. As of Jun 30, 2026 it held $9.9 million in cash and investments and $6.7 million in total debt.
Revenue
$8.17M
+21.4% vs year-ago quarter
Net income
$-7.42M
-8.3% vs year-ago quarter
Operating cash flow
$-4.67M
-33.9% vs year-ago quarter
Free cash flow
—
EPS
$-0.64
+67.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
11.78M
+151.6% vs year-ago quarter
Net cash
$3.21M
Q2 FY2026
Operating margin
-106.7%
TTM
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BNGO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411690
- Former names
- BioNano Genomics, Inc (until Oct 20, 2021); Bionano Genomics, Inc (until Oct 20, 2021); BioNanomatrix Inc (until Mar 24, 2011)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $8.2M | $6.7M | $8.0M | $7.4M | $6.7M |
| Operating income | -$7.2M | -$7.9M | -$8.5M | -$8.5M | -$7.8M |
| Net income | -$7.4M | -$8.3M | -$7.9M | -$8.5M | -$6.9M |
| Diluted EPS | -$0.64 | -$0.76 | -$0.78 | -$1.59 | -$1.99 |
| Operating cash flow | -$4.7M | -$5.7M | -$4.2M | -$5.9M | -$3.5M |
| Total assets | $47.6M | $64.8M | $73.6M | $79.1M | $76.0M |
| Total liabilities | $16.0M | $27.3M | $29.2M | $29.3M | $30.6M |
| Stockholders' equity | $31.6M | $37.5M | $44.4M | $49.8M | $45.4M |
| Cash and investments | $9.9M | $14.4M | $19.3M | $21.6M | $16.4M |
| Total debt | $6.7M | $6.9M | $6.9M | $7.4M | $7.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Other events
|
May 28, 2026 | May 28, 2026 |
All 627 Bionano Genomics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.